2/27
12:58 pm
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
11:44 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
11:44 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
08:10 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
2/26
07:31 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $14.00.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $14.00.
2/26
05:42 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
05:42 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
04:58 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/26
04:58 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/23
08:13 am
cogt
Rating for COGT
High
Report
Rating for COGT
2/23
08:13 am
cogt
Rating for COGT
High
Report
Rating for COGT
2/12
08:09 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
2/12
06:30 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/12
06:30 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/8
07:35 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/8
07:35 am
cogt
Rating for COGT
Low
Report
Rating for COGT
2/8
07:16 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $11.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $11.00 price target on the stock.